Zentalis Pharmaceuticals Llc (ZNTL)

Zentalis Pharmaceuticals Llc (ZNTL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $209M; returns 1 day -8.3%, 1 week +3.8%, 1 year +34.8%.

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, focused on the discovery and development of differentiated small molecule therapeutics targeting fundamental biological pathways of cancers. The company's primary asset and sole current focus is azenosertib (formerly ZN-c3), a potentially first-in-class and best-in-class oral WEE1 inhibitor.

Groups ZNTL belongs to

• Biotechnology
• Clinical Stage Biotech
• Clinical Stage Biopharma
• Biopharmaceutical
• Oncology
• Cancer Therapeutics
• Ovarian Cancer
• Unmet Medical Needs
• Pharmaceuticals

ZNTL financial model: income statement, cash flow and balance sheet